Loopbaan van Will West
Eerdere bekende functies van Will West
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Odontis Ltd.
Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Corporate Officer/Principal | 20-11-2009 | 18-01-2011 |
Procter & Gamble Health & Beauty Care | Corporate Officer/Principal | - | - |
Opleiding van Will West
London Business School | Masters Business Admin |
Statistieken
Internationaal
Verenigd Koninkrijk | 3 |
Verenigde Staten | 2 |
Operationeel
Corporate Officer/Principal | 2 |
Masters Business Admin | 1 |
Sectoraal
Consumer Services | 2 |
Miscellaneous | 2 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Procter & Gamble Health & Beauty Care | Miscellaneous |
Odontis Ltd.
Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Commercial Services |